Journal of International Psychiatry

Objective: To explore the effect of mindfulness cognitive therapy on venlafaxine in patients with depression and quality of life. METHODS: One hundred patients with depression who were admitted to our hospital from February 2018 to February 2019 were the main subjects of this study. They were divided into groups by computer randomization. One group was treated with venlafaxine as a regular group, and the other group was treated with venlafaxine supplemented with mindfulness cognitive therapy as a research group. There were 50 cases in each group. The clinical efficacy, quality of life, mental state, and thalamic adrenal pituitary hormone levels were compared between the two groups. RESULTS: The overall efficacy of the study group was higher than that of the conventional group, and the difference between the groups was significant (p<0.05). The SF-36 quality of life scale of the study group was higher than that of the conventional group, and the HAMD depression score was lower than that of the conventional group. (p<0.05); the levels of ACTH (adrenocorticotropic hormone), CRH (corticotropin releasing hormone), CORT (corticosterone), Cor (cortisol) in the study group were significantly lower than those in the conventional group, and the differences between groups Significant (p < 0.05). Conclusion: The treatment of venlafaxine in patients with depression is supplemented by mindfulness cognitive therapy, which can not only improve the hormone level of the hypothalamic adrenal pituitary axis, but also reduce the negative emotions of patients, further improve the quality of life of patients, and the clinical effect is remarkable. It is worthy of recommendation and popularization in the clinic.

mindfulness cognitive therapy; venlafaxine; depression; psychological state; quality of life